IMMU - Immunomedics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
25.40
-0.07 (-0.27%)
At close: 4:00PM EDT

25.40 0.00 (0.00%)
After hours: 5:00PM EDT

Stock chart is not supported by your current browser
Previous Close25.47
Open25.47
Bid25.50 x 3100
Ask25.90 x 900
Day's Range25.19 - 25.80
52 Week Range7.17 - 26.48
Volume1,204,598
Avg. Volume2,639,044
Market Cap4.583B
Beta3.70
PE Ratio (TTM)N/A
EPS (TTM)-1.54
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.00
Trade prices are not sourced from all markets
  • ACCESSWIRE7 days ago

    Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks

    WallStEquities.com observes the following stocks for today: Five Prime Therapeutics Inc. (NASDAQ: FPRX), Genocea Biosciences Inc. (NASDAQ: GNCA), Immunomedics Inc. (NASDAQ: IMMU), and Incyte Corp. (NASDAQ: INCY). Shares in South San Francisco, California headquartered Five Prime Therapeutics Inc. rose 1.02%, ending Tuesday's trading session at $16.87.

  • How Financially Strong Is Immunomedics Inc (NASDAQ:IMMU)?
    Simply Wall St.21 days ago

    How Financially Strong Is Immunomedics Inc (NASDAQ:IMMU)?

    Stocks with market capitalization between $2B and $10B, such as Immunomedics Inc (NASDAQ:IMMU) with a size of US$4.32b, do not attract as much attention from the investing community as doRead More...

  • Barrons.com26 days ago

    [$$] Immunomedics Chairman Buys $19M More in Stock

    Two weeks ago, B. Riley analyst Madhu Kumar gushed about Immunomedics, writing in a report that the biotech could have a “blockbuster cancer drug” in IMMU-132, an antibody-drug conjugate that had shown promise in disrupting “multiple solid cancers.” Kumar initiated coverage of the biotech on June 6 at Buy with a $53 price target. On Friday, Immunomedics (IMMU) Chairman Behzad Aghazadeh bought $18.5 million worth of the company’s stock through venBio Select Fund, a hedge fund where he serves as managing partner and portfolio manager. Aghazadeh bought 575,000 Immunomedics shares through the company’s public offering at $24 each, and went to the open market to buy another 200,000 shares for a better average per-share price of $23.39.

  • ACCESSWIRE27 days ago

    Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Immunomedics

    NEW YORK, NY / ACCESSWIRE / June 21, 2018 / U.S. markets were mixed Wednesday as global trade concerns continue to be a focus. The Nasdaq and S&P 500 Index posted gains driven by deal making activities ...

  • GlobeNewswirelast month

    Immunomedics Announces Closing of Public Offering of Common Stock

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of the Company’s common stock at a public offering price of $24.00 per share. The total net proceeds from the offering for Immunomedics are estimated to be approximately $260 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

  • GlobeNewswirelast month

    Immunomedics Announces Pricing of Public Offering of Common Stock

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $24.00 per share, representing gross proceeds of approximately $276 million. In addition, Immunomedics has granted the underwriters a 30-day option to purchase up to 1,725,000 additional shares of common stock. Immunomedics intends to use the net proceeds from the proposed offering for the acceleration of the clinical development program of sacituzumab govitecan, manufacturing process improvements as well as for working capital and general corporate purposes.

  • TheStreet.comlast month

    The Charts of Immunomedics Look Very Bullish Now

    In this daily bar chart of IMMU, below, we can see that prices have tripled in the past 12 months. The daily On-Balance-Volume (OBV) line has been moving higher the past year telling us that buyers of IMMU have been more aggressive. The Moving Average Convergence Divergence (MACD) oscillator is well above the zero line but it could cross to a take profits sell signal.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 11) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...

  • GlobeNewswirelast month

    Immunomedics Announces Proposed Public Offering of Common Stock

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it has commenced an underwritten public offering of $275,000,000 of shares of its common stock. In addition, Immunomedics expects to grant the underwriters a 30-day option to purchase up to an aggregate of an additional $41,250,000 of shares of common stock sold in connection with the offering at the public offering price. Immunomedics intends to use the net proceeds from the proposed offering for the acceleration of the clinical development program of sacituzumab govitecan, manufacturing process improvements as well as for working capital and general corporate purposes.

  • CNBClast month

    After-hours buzz: RH, PLAY and more

    Check out the companies making headlines after the bell: Shares of Restoration Hardware RH climbed more than 20 percent after the bell, after the luxury home furnishings company reported mixed first quarter earnings that beat analyst expectations, but missed on revenue.

  • Immunomedics (IMMU) Soars: Stock Adds 10.3% in Session
    Zackslast month

    Immunomedics (IMMU) Soars: Stock Adds 10.3% in Session

    Immunomedics (IMMU) shares rose more than 10% in the last trading session, amid huge volumes.

  • ACCESSWIRElast month

    Today's Research Reports on Stocks to Watch: Genomic Health and Immunomedics

    NEW YORK, NY / ACCESSWIRE / June 5, 2018 / Genomic Health saw a major boost in trading price on Monday, with shares hitting a new high after encouraging results were published in The New England Journal of Medicine regarding data from the Trial Assigning Individualized Options for Treatment (TAILORx). The trial had found that about 70 percent of women with early-stage breast cancer and an intermediate risk of cancer recurrence can safely pass on doing chemotherapy. Shares of Immunomedics also saw gains after announcing that it has entered into a clinical collaboration with Clovis Oncology.

  • Why Fossil Group, Companhia Siderurgica Nacional, and Immunomedics Jumped Today
    Motley Foollast month

    Why Fossil Group, Companhia Siderurgica Nacional, and Immunomedics Jumped Today

    Find out which stock had the best news today.

  • Why A Tie-Up With Clovis Helped This Biotech Spike To An 18-Year High
    Investor's Business Dailylast month

    Why A Tie-Up With Clovis Helped This Biotech Spike To An 18-Year High

    Immunomedics popped to an 18-year high Monday after it unveiled plans for its cancer drug, including a tie-up with Clovis Oncology to test a regimen.

  • Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today
    Motley Foollast month

    Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today

    It was off to the races earlier today following compelling data on Immunomedics' lead drug.

  • Benzingalast month

    5 Biotech Stocks Moving On ASCO Presentations

    The American Society of Clinical Oncology annual meeting started Friday at McCormick Place in Chicago and is set to conclude Tuesday.  With several companies presenting on their respective cancer pipeline ...

  • GlobeNewswirelast month

    Immunomedics Provides Business Update at the ASCO 2018 Investor Event

    Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced a comprehensive overview of its clinical development plan for sacituzumab govitecan, Immunomedics’ lead ADC, at the Company’s Investor Event during the 2018 ASCO Annual Meeting.

  • GlobeNewswirelast month

    Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers

    Companies to Start Phase 1/ 2 Study to Evaluate the Combination of Rubraca ® and Sacituzumab Govitecan in Patients with Metastatic Triple-negative Breast Cancer and Metastatic Urothelial Cancer. BOULDER, ...

  • GlobeNewswirelast month

    Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer

    Confirmed Overall Response Rate of 31 Percent; with Median Duration of Response of 7.4 Months and Median Progression-free Survival of 6.8 Months. CHICAGO, June 03, 2018-- Immunomedics, Inc.,, a leading ...

  • GlobeNewswire2 months ago

    Immunomedics Announces Pivotal Study of Sacituzumab Govitecan in Patients With Locally Advanced or Metastatic Urothelial Cancer

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company plans to initiate a Phase 2 pivotal TROPHY U-01 study of sacituzumab govitecan, the Company’s lead investigational ADC, as a single agent in patients with locally advanced or metastatic urothelial cancer (mUC) who have relapsed after a platinum-based regimen and/or immune checkpoint inhibitor (CPI) therapy. “Urothelial cancer patients who have relapsed after, or are refractory to platinum chemotherapy and the recently approved CPI treatments, have a significant unmet need with few available treatment options,” remarked Dr. Rob Iannone, Head of R&D and Chief Medical Officer of Immunomedics.

  • GlobeNewswire2 months ago

    Immunomedics to Present at Jefferies 2018 Global Healthcare Conference

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a science-based and innovation-focused biopharmaceutical company committed to the development and worldwide commercialization of its unique and proprietary antibody-drug conjugate platform, today announced that Michael Pehl, President and Chief Executive Officer, will present an overview of the Company at Jefferies 2018 Global Healthcare Conference at 8:30 a.m. Eastern Time on Wednesday, June 6, 2018, in New York City. A live audio webcast of the presentation will be accessible from the Company’s website at https://immunomedics.com/investors.

  • GlobeNewswire2 months ago

    Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration

    Immunomedics, Inc., (IMMU) (“Immunomedics” or the “Company”), a science-based and innovation-focused biopharmaceutical company committed to the development and worldwide commercialization of its unique and proprietary antibody-drug conjugate (ADC) platform, today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who previously received at least two prior therapies for metastatic disease. If approved, sacituzumab govitecan would be the first and only ADC approved for the treatment of mTNBC.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of IMMU earnings conference call or presentation 9-May-18 9:00pm GMT

    Q3 2018 Immunomedics Inc Earnings Call

  • Immunomedics Announces Positive Phase 2 Results
    Market Realist2 months ago

    Immunomedics Announces Positive Phase 2 Results

    Today, Immunomedics (IMMU) announced positive results from a Phase 2 trial evaluating its investigational antibody drug conjugate (or ADC) sacituzumab govitecan in patients suffering from estrogen receptor-positive (or ER+)/human epidermal growth factor receptor 2-negative (or HER2-) metastatic breast cancer who have previously received at least two therapies. The investigational ADC therapy demonstrated an overall response rate of 31% in these heavily pretreated patients. Immunomedics plans to file its first biologics license application with the FDA later this month for the approval of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer (mTNBC).

  • Immunomedics Inc (NASDAQ:IMMU): Time For A Financial Health Check
    Simply Wall St.2 months ago

    Immunomedics Inc (NASDAQ:IMMU): Time For A Financial Health Check

    Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Immunomedics Inc (NASDAQ:IMMU), with a market cap of US$3.14B, often get neglectedRead More...